Drug Executive Collapses During Oval Office Event
During a press conference in the Oval Office, a drug executive suddenly collapsed as President Donald Trump announced a new agreement with pharmaceutical companies to lower prices on obesity medications.
Incident Details
The press conference, held on Thursday, was focused on a deal involving Eli Lilly and Novo Nordisk to expand insurance coverage and reduce costs for their obesity drugs, Zepbound and Wegovy. David Ricks, CEO of Eli Lilly, was speaking when he noticed the executive was unwell.
"Are you okay? Gordon, are you okay?" asked David Ricks, noticing the man collapse.
The individual who fainted was identified as Gordon Findlay, the global brand director for Novo Nordisk. Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, immediately assisted as Findlay fell to his knees and passed out.
Response and Aftermath
Following the incident, the press was asked to leave the room while Findlay received attention. Health and Human Services Secretary was also present during the event. Approximately 30 minutes later, the press conference resumed, and President Trump provided an update on Findlay's condition.
President Trump gave an update on the executive's health when the conference continued.
Summary
This unexpected medical emergency briefly interrupted an announcement aimed at reducing the cost of key obesity drugs, highlighting both the high-profile nature of the event and the prompt response by officials present.
Author's summary: A drug executive fainted during a key White House event on lowering obesity drug prices, with Dr. Mehmet Oz and officials responding swiftly before the conference resumed.